Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Current Deferred Revenue: ₺0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IST:ONCSM Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS IST:ONCSM
79 GF Score
Price ₺261.25
GF Value ₺254.73
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Oncosem Onkolojik Sistemlernayi ve Ticaret AS Current Deferred Revenue?

Oncosem Onkolojik Sistemlernayi ve Ticaret AS IST:ONCSM +4.50% 79 Current Deferred Revenue is ₺0.0 Mil as of Mar. 2026. GuruFocus rates IST:ONCSM with a GF Score™ of 79/100 and a GF Value™ of ₺254.73 (Fairly Valued). The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current deferred revenue for the quarter that ended in Mar. 2026 was ₺0.0 Mil.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Current Deferred Revenue Related Terms

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Current Deferred Revenue Chart

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Quarterly Data
Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
IST:ONCSM
79GF Score
Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS IST:ONCSM
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of ₺0.0 Mil mean?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) has a Current Deferred Revenue of ₺0.0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Current Deferred Revenue too high?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current Current Deferred Revenue is ₺0.0 Mil. Overall, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Current Deferred Revenue compare to ABT and SYK?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Current Deferred Revenue of ₺0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current Current Deferred Revenue is ₺0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) is currently considered Fairly Valued. The stock's GF Value™ is ₺254.73, compared to a current price of ₺261.25 — trading 2.6% above its estimated fair value. The current Current Deferred Revenue is ₺0.0 Mil. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM), the current Current Deferred Revenue is ₺0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Overvalued in 2026?

Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock appears to be overvalued. The current stock price of ₺261.25 is trading 2.6% above its estimated GF Value™ of ₺254.73. GuruFocus considers Oncosem Onkolojik Sistemlernayi ve Ticaret AS to be Fairly Valued.

Key valuation signals for IST:ONCSM:

  • Current Deferred Revenue: ₺0.0 Mil
  • GF Value™: ₺254.73 vs. price of ₺261.25 (2.6% above fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the IST:ONCSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Business Description

Address Mutlukent Mah. 1988 Cad. No: 12, Cankaya, Ankara, TUR
Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS is specialized in the production of equipment and medical devices used in cancer treatment.
79GF Score

Get the complete analysis for IST:ONCSM

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₺261.25
Price
₺254.73
GF Value